And we have greater liver defatting effects. There are defatting effects to 24 weeks, there’s about 62% percent, ours is 76%. That’s the major driver of MASH resolution and fibrosis improvement.

Hydrogen isotopes in animal organic tissues have been exploited successfully to trace migration (a large literature; see the volume Hobson and Wassenaar, 2019) and are being investigated for ...

Altimmune (NASDAQ:ALT) Inc. reported its fourth-quarter 2024 earnings, revealing a slight beat on EPS forecasts with an actual EPS of -0.33 compared to the forecasted -0.34. Revenue, however, was ...

About Altimmune Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a ...

GAITHERSBURG, Md., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the expansion of its Board of Directors with the ...

He holds a BBA in marketing from the University of Notre Dame. Mr. Durso added, "Pemvidutide is a very exciting product candidate that not only drives significant liver defatting, but also has been ...

Altimmune (NASDAQ:ALT) Inc. reported its fourth-quarter 2024 earnings, revealing a slight beat on EPS forecasts with an actual EPS of -0.33 compared to the forecasted -0.34. Revenue, however, was ...